BV6 induces autoubiquitination and subsequent proteasomal degradation of cIAP1 and cIAP2, and greatly sensitizes cells to TNF-induced necrosis. BV6 significantly enhances the radiosensitization of HCC193 and H460 cells in vitro. BV6 sensitizes both cell lines to radiation (HCC193-DER = 1.38, p < 0.05 at 1 μM BV6; H460-DER = 1.42, p < 0.05 at 5 μM BV6), but a higher concentration of and longer incubation time with BV6 was necessary for H460 cells.
|Cell lines||HCC193 and H460 cells|
|Preparation method||Using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay kit to measure cell viability . Seeding 5000 cells/well into 96-well plates in triplicate. Following adhesion of cells to the wells, adding increasing concentrations of BV6 into different wells.Exposing control groups to the same concentration of DMSO. Addng the final concentrations of 333 μg/mL MTS and 25 μM PMS to each well 24 hours later. After two hours incubation at 37 °C in humidified 5% CO2, read plates at the absorbance of 490-nm on a microplate reader.Calculating relative cell viability of an individual sample by normalizing their absorbance to that of the corresponding control. Using Prism 5.01 to calculate IC50 values . For the TNFα neutralizing antibody assay, exposing cells to 1 and 5 μM BV6 with or without 10 μg/mL infliximab and the assay is performed 24 hours later. Read plates at the absorbance of 490-nm on a microplate reader|
|Incubation time||~48 hours|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro.
Li W, et al. J Thorac Oncol. 2011 Nov;6(11):1801-9. PMID: 21760551.
|Related IAP Products|
SM-164 is a potent cell-permeable and bivalent Smac mimetic which bind to a XIAP protein with a Ki value of 0.56 nM, and binds to cIAP-1 and cIAP-2 proteins with Ki values of 0.31 and 1.1 nM, respectively.
LCL161 is an orally bioavailable SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).
Birinapant (formerly TL32711) is a Smac mimetic acts as antagonist to cIAP1 and cIAP2.
GDC-0152 is a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins with potential antineoplastic activity.
AT-406 is an orally bioavailable potent IAP (inhibitor of apoptosis protein) of XIAP, cIAP1 and cIAP2 with Ki of 66.4 nM, 1.9 nM and 5.1 nM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.